Log In Sign up
The largest database of trusted experimental protocols

STMN1 is a protein that plays a role in the regulation of the microtubule cytoskeleton. It is involved in the disassembly and assembly of microtubules, which are important structures within cells.

Automatically generated - may contain errors

Lab products found in correlation

Anti human foxm1, by Santa Cruz Biotechnology (1 mentions) Histone 3, by Cell Signaling Technology (1 mentions) Silencer select validated sirna, by Thermo Fisher Scientific (1 mentions) Mk2206, by MedChemExpress (1 mentions) Nanog, by Cell Signaling Technology (1 mentions) Sorafenib, by MedChemExpress (1 mentions) Phosphor akt, by Cell Signaling Technology (1 mentions) E cadherin, by Cell Signaling Technology (1 mentions) Regorafenib, by MedChemExpress (1 mentions) β actin, by Cell Signaling Technology (1 mentions) Phosphor erk, by Cell Signaling Technology (1 mentions) Phosphor jnk, by Cell Signaling Technology (1 mentions) Pd98059, by MedChemExpress (1 mentions) Mmp 9, by Cell Signaling Technology (1 mentions) N cadherin, by Cell Signaling Technology (1 mentions) Vimentin, by Cell Signaling Technology (1 mentions)

Spelling variants of this product

Anti-STMN1 (2 citations)

3 protocols using stmn1

1

Protein Expression Profiling of LIHC, GC, and CRC

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tissue microarrays of human LIHC, GC and CRC were obtained from the Department of Pathology, Fourth Military Medical University (China, Xi’an), and was stained with anti-human FoxM1 (Santa Cruz Biotechnology; sc-376471; 1:50) and STMN1 (Cell Signaling Technology, 13655S; 1:100) antibodies. The slides were scanned using Pannoramic (Santa Clara, CA, USA) MIDI and quantified using Quant center. The correlation of protein expression was analyzed using GraphPad Prism (Version 6; La Jolla, CA, USA).
Liu J., Li J., Wang K., Liu H., Sun J., Zhao X., Yu Y., Qiao Y., Wu Y., Zhang X., Zhang R, & Yang A. (2021). Aberrantly high activation of a FoxM1–STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers. Signal Transduction and Targeted Therapy, 6, 42.
+ Open protocol
+ Expand
2

Gefitinib and Sorafenib Inhibit EMT

Check if the same lab product or an alternative is used in the 5 most similar protocols
Gefitinib was purchased from J&K Chemical (Beijing, China). Sorafenib, regorafenib, MK2206 (AKT inhibitor), and PD98059 (ERK inhibitor) were obtained from MedChem Express (Princeton, NJ, USA). The primary antibodies against Sox2, Oct4, Nanog, STMN1, E-cadherin, N-cadherin, vimentin, ERK, phosphor–ERK, Akt, phosphor–Akt, JNK, phosphor–JNK, MMP-9, Histone3, and β-actin were obtained from Cell Signaling Technology. The primary antibodies against FOXM1, E2F1, and MMP2 were purchased from Abcam. Silencer Select Validated siRNAs against STMN1 and FOXM1 were obtained from Life Technologies, Carlsbad, CA, USA.
Li M., Yang J., Zhou W., Ren Y., Wang X., Chen H., Zhang J., Chen J., Sun Y., Cui L., Liu X., Wang L, & Wu C. (2017). Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer. British Journal of Cancer, 117(7), 974-983.
+ Open protocol
+ Expand
3

Immunohistochemical Staining Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tissue sections were stained following previously reported protocol,12 (link) using antibodies against human DPYL2 (1:500; LSBio), GNAQ (1:100; Abcam), RSSA (1:150; LSBio), RUVB1 (1:100; Atlas Antibodies), and STMN1 (1:50; Cell Signaling). Staining intensity of cases represented in triplicate was evaluated by two independent observers (B.W., S.O.) as follows: 0, no staining; 1, weak; 2, moderate; and 3, strong. Staining intensity was then multiplied by stained tumor cell percentage to obtain the final staining score (range, 0–300).
Ocak S., Friedman D.B., Chen H., Ausborn J.A., Hassanein M., Detry B., Weynand B., Aboubakar F., Pilette C., Sibille Y, & Massion P.P. (2014). Discovery of New Membrane-Associated Proteins Overexpressed in Small-Cell Lung Cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 9(3), 324-336.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!